ADCT-301
Pro00105771
Phase 2 small_molecule terminated
Quick answer
ADCT-301 for Acute Myeloid Leukemia (AML) is a Phase 2 program (small_molecule) at ADC Therapeutics SA with 1 ClinicalTrials.gov record(s).
Program details
- Company
- ADC Therapeutics SA
- Indication
- Acute Myeloid Leukemia (AML)
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- terminated